Trials / Completed
CompletedNCT06311032
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
Detailed description
The study will employ a survey design that poses physicians with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. This will be a double-blinded randomized survey study, featuring two arms. Providers will be randomized to either be provided with, or not provided with a risk stratification tool (DART-1) when presented with their clinical case vignettes.
Conditions
Timeline
- Start date
- 2023-03-29
- Primary completion
- 2023-06-28
- Completion
- 2023-07-28
- First posted
- 2024-03-15
- Last updated
- 2024-03-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06311032. Inclusion in this directory is not an endorsement.